You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
透视港股通丨内资增持海吉亚医疗,抛售小米

北水总结

5月28日港股市场,北水净流出18.43亿,其中港股通(沪)净流出11.12亿港元,港股通(深)净流出7.31亿港元。

北水净买入最多的个股是海吉亚医疗(06078)、比亚迪电子(00285)、药明生物(02269)。北水净卖出最多的个股是小米集团-W(01810)、中国移动(00941)、赣锋锂业(01772)。

数据来源:盈立智投APP

十大成交活跃股

数据来源:盈立智投APP

个股点评

海吉亚医疗(06078)获净买入2.51亿港元。消息面上,海吉亚医疗公告,计划以不超过6.416亿元收购广西省贺州广济医院99%的股权。中金发布研报称,被收购标的经营情况良好。贺州广济医院为一家民营营利性三级综合医院,科室包括骨科、肾内科、泌尿外科、肿瘤科、急救科等;贺州地区肿瘤需求旺盛,供给缺口带来发展契机;此次收购有望加强华南地区布局。该行维持其“跑赢行业”评级,考虑近期板块估值上行,上调目标价13%至86.8港元。

比亚迪电子(00285)获净买入2.32亿港元。消息面上,近日市场传出消息称,比亚迪电子的电子烟业务已经完成专利布局,产线进入试生产,预计6月可能进入大规模量产,具体进度取决于客户认证和需求,测算全部40条产线满产产值或将接近百亿水平。比亚迪有关负责人回应称:电子烟业务以给品牌客户做代工为主,没有独立上市计划。

药明生物(02269)获净买入1.94亿港元。消息面上,药明生物和临床阶段生物制药公司OncoC4宣布,双方就OncoC4的全部研发管线建立了独家CDMO合作伙伴关系。OncoC4的研发管线包括新一代CTLA-4抗体ONC-392,目前该抗体正在美国和中国进行I期临床试验。根据协议,药明生物将作为独家CDMO合作伙伴提供一体化研发和生产服务,满足OncoC4的生物药从早期研究、临床前至商业化阶段的需求。此外,5月24日,摩根大通增持药明生物约102.56万股,每股作价108.6527港元,涉资约1.11亿港元。

思摩尔国际(06969)获净买入1.01亿港元。消息面上,汇丰发布研报称,思摩尔国际仍然处于良好的行业定位,主要因为:预计电子烟设备行业将以31%的CAGR速度保持增长;海外监管制度禁止下游电子烟品牌更换设备供应商,因为雾化器和设备是上市前产品发布批准的一部分;公司是陶瓷雾化器技术的领军者,如果下游品牌更换雾化器供应商,电子蒸汽的味道和用户体验将会发生改变。汇丰表示,继续看好思摩尔国际发展前景。该行对公司盈利预测保持不变,维持思摩尔国际目标价65港元和“买入”评级。

小米集团-W(01810)今日股价冲高回落,北水资金随市抛售,全天净卖出额达9.25亿港元。消息面上,小米集团近日发布首季业绩,该集团取得收入人民币768.82亿元,同比增加54.7%;经调整净利润60.69亿元,同比增加163.8%,创单季度历史新高。绩后获多家大行发布研报唱好。小摩表示,小米Q1财报正面,上调小米目标价至35港元;瑞银则表示,小米手机、广告业务及毛利亮丽,上调目标价至30港元;中信称小米业绩显著超市场一致预期,维持“买入”评级。

此外,舜宇光学(02382)、维亚生物(01873)分别获净买入1.58亿、732万港元。而中移动(00941)、赣锋锂业(01772)、中芯国际(00981)分别遭净卖出6.69亿、3.08亿、8399万港元。

当日港股通净买入和净卖出排行榜

(港股通持股比例排行,交易所数据T+2日结算)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account